Contagion Live News Network: Pneumococcal Conjugate Vaccine V114

An overview of today's top infectious disease stories.

Investigational PCV Meets Safety and Immunogenicity Objectives in Initial Phase 3 Studies

Merck has announced results from 2 initial Phase 3 studies, PNEU-FLU and PNEU-WAY, evaluating the firm’s 15-valent pneumococcal conjugate vaccine (PCV).

V114 uses pneumococcal polysaccharides from 15 serotypes conjugated to a CRM197 carrier protein, including serotypes 22F and 33F. These serotypes are widely associated with invasive pneumococcal disease globally and are not found in the currently licensed pneumococcal conjugate vaccine for adults.

“Certain populations are at greater risk for pneumococcal disease, reinforcing the importance of investigating new interventions focused on their specific needs,” said Luwy Musey, MD, executive director in biologics, vaccine clinical research, at Merck Research Laboratories. “Results from these first two Phase 3 studies of V114 are encouraging and we look forward to sharing additional data in the future from our ongoing clinical development program, including our pivotal studies assessing the immunogenicity of V114 and its potential to protect against the serotypes most likely to cause invasive disease.” Read more.

CONTAGION LIVE NEWS NETWORK - JUNE 23, 2020:

(Assistant Editor Grant Gallagher gives an overview of the day's top stories.)